• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
XLRN

XLRN

Acceleron Pharma Inc.

NASDAQHealthcareBiotechnologyUS

USD178.75

+0.00 (+0.00%)

Company Profile

CEO

Habib Dable

IPO Date

2013-09-18

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$179.85

Prev. Close

$178.75

Day Low

$177.20

Day High

$179.85

52W Low

$111.75

52W High

$189.99

Volume

7.88M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

29.2%

Avg Negative

2.9%

Avg Neutral

67.9%

News Feed

Acceleron Announces Second Quarter 2021 REBLOZYL® Net Sales

Business Wire·7/28/2021·↑ positive

Acceleron to Webcast Second Quarter 2021 Financial Results on August 5, 2021

Business Wire·7/26/2021·↑ positive

Ongoing Treatment With Acceleron's Sotatercept Continue To Show Benefit In PAH Patients

Benzinga·5/19/2021·↑ positive

Acceleron Presents Preliminary Data from the SPECTRA Phase 2 Trial of Sotatercept in Pulmonary Arterial Hypertension (PAH) at the American Thoracic Society 2021 International Conference

Business Wire·5/19/2021·↑ positive

Acceleron Pharma Inc. (XLRN) CEO Habib Dable on Q1 2021 Results - Earnings Call Transcript

Seeking Alpha·5/9/2021·↓ negative

Acceleron Pharma (XLRN) Reports Q1 Loss, Misses Revenue Estimates

Zacks Investment Research·5/6/2021·↑ positive

Acceleron Announces First Quarter 2021 REBLOZYL® Net Sales

Business Wire·4/29/2021·↑ positive

Acceleron: Neutral On Stock Price Gains

Seeking Alpha·4/5/2021·↑ positive

Why Is Acceleron (XLRN) Up 0.5% Since Last Earnings Report?

Zacks Investment Research·3/27/2021·↓ negative

Acceleron (XLRN) Stock Jumps 3.3%: Will It Continue to Soar?

Zacks Investment Research·3/22/2021·↑ positive